QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ansari, K. S. Articles by Tatton, W. G. Search for Related Content PubMed PubMed Citation Articles by Ansari, K. S. Articles by Tatton, W. G.

 Previous Article  |  Next Article 

Journal of Neuroscience, Vol 13, 4042-4053, Copyright © 1993 by Society for Neuroscience

ARTICLE

Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition

KS Ansari, PH Yu, TP Kruck and WG Tatton
Department of Physiology, University of Toronto, Ontario, Canada.

The role of monoamine oxidase B (MAO-B) in R(-)-deprenyl-mediated rescue of rat facial motoneurons axotomized at postnatal day 14 (P14) was investigated using the (+)- and (-)-enantiomers of deprenyl [S(+)- deprenyl and R(-)-deprenyl]. Previously, doses of R(-)-deprenyl sufficient to inhibit MAO-B were shown to increase the survival of motoneurons following an apparent loss of target-derived trophic support caused by axotomy in P14 rats. In the present experiments, motoneuronal survival was measured 21 d after unilateral facial nerve transection at P14. The animals were treated with saline or doses of R(- )- or S(+)-deprenyl ranging from 0.001 to 10 mg/kg every 2 days (/2d). Frontal serial 10 microns sections were taken through the length of the facial nuclei ipsilaterally and contralaterally to the facial nerve transections. Every third section was immunoreacted for an antibody against ChAT to identify the motoneuron somata, while every adjacent third section was Nissl stained to assess motoneuronal survival. A second series of P14 rats was treated with similar doses of the two deprenyl enantiomers or saline and the brainstems removed for measurement of MAO-A and MAO-B activity at 4 hr after the treatments. Averages of 24% of the facial motoneurons survived axotomy with either saline treatment or 0.001 mg/kg/2d doses of R(-)-deprenyl. Doses of R(- )-deprenyl of 0.005, 0.01, and 10.0 mg/kg/2d increased the surviving facial motoneuron to 38%, 51%, and 48%, respectively, indicating an ED50 of about 0.005 mg/kg/2d. Doses of S(+)-deprenyl as high as 10 mg/kg/2d did not increase motoneuronal survival, revealing a stereospecificity for the increased survival of at least 2000-fold. The ED50 for MAO-B inhibition in the P14 brainstem was approximately 0.1 mg/kg for the (-)-enantiomer and 2.0 mg/kg for the (+)-enantiomer, revealing a 20-fold higher sensitivity of the enzyme toward the (-)- enantiomer in the P14 rat brainstem. A dose of 10 mg/kg of S(+)- deprenyl inhibited about 65% of brainstem MAO-B activity without increasing motoneuronal survival, whereas 0.005 and 0.01 mg/kg of R(-)- deprenyl increased motoneuronal survival without significant inhibition of brainstem MAO-B activity.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				G. Schifitto, J. Zhang, S. R. Evans, N. Sacktor, D. Simpson, L. L. Millar, V. L. Hung, E. N. Miller, E. Smith, R. J. Ellis, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment Neurology, September 25, 2007; 69(13): 1314 - 1321. [Abstract] [Full Text] [PDF]

				M. R. Hara, B. Thomas, M. B. Cascio, B.-I. Bae, L. D. Hester, V. L. Dawson, T. M. Dawson, A. Sawa, and S. H. Snyder Neuroprotection by pharmacologic blockade of the GAPDH death cascade PNAS, March 7, 2006; 103(10): 3887 - 3889. [Abstract] [Full Text] [PDF]

				L. E. Dyck and B. A. Davis Inhibition of Rat Liver Microsomal CYP1A2 and CYP2B1 Activity by N-(2-Heptyl)-N-methyl-propargylamine and by N-(2-Heptyl)-propargylamine Drug Metab. Dispos., August 1, 2001; 29(8): 1156 - 1161. [Abstract] [Full Text] [PDF]

				G. W. Carlile, R. M. E. Chalmers-Redman, N. A. Tatton, A. Pong, K. E. Borden, and W. G. Tatton Reduced Apoptosis after Nerve Growth Factor and Serum Withdrawal: Conversion of Tetrameric Glyceraldehyde-3-Phosphate Dehydrogenase to a Dimer Mol. Pharmacol., January 1, 2000; 57(1): 2 - 12. [Abstract] [Full Text]

				A. Di Rocco, R. Roesler, J. Quevedo, R. Walz, M. Bianchin, and N. Sacktor A randomized, double-blind, placebo-controlled trial of deprenyl and thiotic acid in HIV-associated cognitive impairment Neurology, June 1, 1999; 52(9): 1920 - 1920. [Full Text] [PDF]

				M. S. Saporito, E. M. Brown, M. S. Miller, and S. Carswell CEP-1347/KT-7515, an Inhibitor of c-jun N-Terminal Kinase Activation, Attenuates the 1-Methyl-4-Phenyl Tetrahydropyridine-Mediated Loss of Nigrostriatal Dopaminergic Neurons In Vivo J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 421 - 427. [Abstract] [Full Text]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help